Nigral grafts in animal models of Parkinson's disease. Is recovery beyond motor function possible?

Progress in Brain Research

Volumn 200, Issue , 2012, Pages 113-142

  Lelos, Mariah J ^a   Dowd, Eilís ^b   Dunnett, Stephen B ^a,c  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cognition; Dopamine; Nigral transplantation; Nonmotor function; Operant tests; Parkinson's disease; Rodent models; Striatal function

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ARTICLE; BRAIN FUNCTION; CELL TRANSPLANTATION; COHORT ANALYSIS; HUMAN; MEMORY DISORDER; MOTOR PERFORMANCE; NEUROMODULATION; NEUROTRANSMISSION; NIGRAL TRANSPLANTATION; PARKINSON DISEASE; PRIORITY JOURNAL; RECOGNITION; TREATMENT INDICATION; WORKING MEMORY;

EID: 84870274718     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/B978-0-444-59575-1.00006-5     Document Type: Chapter

References (152)

1. Aarts E., van Holstein M., Cools R. Striatal dopamine and the interface between motivation and cognition. Front. Psychol. 2011, 2:163.
2. Aarts E., Helmich R.C., Janssen M.J., Oyen W.J., Bloem B.R., Cools R. Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss. Neuroimage 2012, 59:3339-3346.
3. Abrous D.N., Shaltot A.R.A., Torres E.M., Dunnett S.B. Dopamine-rich grafts in the neostriatum and/or nucleus accumbens: effects on drug-induced behaviours and skilled paw-reaching. Neuroscience 1993, 53:187-197.
4. Abrous D.N., Torres E.M., Dunnett S.B. Dopaminergic grafts implanted into the neonatal or adult striatum: comparative effects on rotation and paw reaching deficits induced by subsequent unilateral nigrostriatal lesions in adulthood. Neuroscience 1993, 54:657-668.
5. Aguayo A.J., Björklund A., Stenevi U., Carlstedt T. Fetal mesencephalic neurons survive and extend long axons across peripheral nervous system grafts inserted into the adult rat striatum. Neurosci. Lett. 1984, 45:53-58.
6. Arenas E. Towards stem cell replacement therapies for Parkinson's disease. Biochem. Biophys. Res. Commun. 2010, 396:152-156.
7. Arnsten A.F. Catecholamine modulation of prefrontal cortical cognitive function. Trends Cogn. Sci. 1998, 2:436-447.
8. Backlund E.O., Granberg P.O., Hamberger B., Knutsson E., Mårtensson A., Sedvall G., Seiger Å., Olson L. Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J. Neurosurg. 1985, 62:169-173.
9. Ballard I.C., Murty V.P., Carter R.M., MacInnes J.J., Huettel S.A., Adcock R.A. Dorsolateral prefrontal cortex drives mesolimbic dopaminergic regions to initiate motivated behavior. J. Neurosci. 2011, 31:10340-10346.
10. Barker R. Cell therapies and Parkinson's disease: where next? Interviewed by Emily Culme-Seymour. Regen. Med. 2010, 5:857-861.
11. Barker R.A., Dunnett S.B. The biology and behaviour of intracerebral adrenal transplants in animals and man. Rev. Neurosci. 1993, 4:113-146.
12. Barker R.A., Fricker R.A., Abrous D.N., Fawcett J.W., Dunnett S.B. A comparative study of the preparation techniques for improving the viability of nigral grafts using vital stain, in vitro cultures and in vivo grafts. Cell Transplant. 1995, 4:173-200.
13. Bédard M.A., el Massioui F., Malapani C., Dubois B., Pillon B., Renault B., Agid Y. Attentional deficits in Parkinson's disease: partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic alpha 1 agonist. Clin. Neuropharmacol. 1998, 21:108-117.
14. Bertram K., Williams D.R. Visual hallucinations in the differential diagnosis of parkinsonism. J. Neurol. Neurosurg. Psychiatry 2012, 83:448-452.
15. Björklund A., Stenevi U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral transplants. Brain Res. 1979, 177:555-560.
16. Björklund A., Dunnett S.B., Stenevi U., Lewis M.E., Iversen S.D. Reinnervation of the denervated striatum by substantia nigra transplants: functional consequences as revealed by pharmacological and sensorimotor testing. Brain Res. 1980, 199:307-333.
17. Björklund A., Schmidt R.H., Stenevi U. Functional reinnervation of the neostriatum in the adult rat by use of intraparenchymal grafting of dissociated cell suspensions from the substantia nigra. Cell Tissue Res. 1980, 212:39-45.
18. Björklund A., Stenevi U., Schmidt R.H., Dunnett S.B., Gage F.H. Intracerebral grafting of neuronal cell suspensions. II. Survival and growth of nigral cell suspensions implanted in different brain sites. Acta Physiol. Scand. Suppl. 1983, 522:9-18.
19. Björklund A., Lindvall O., Isacson O., Brundin P., Wictorin K., Strecker R.E., Clarke D.J., Dunnett S.B. Mechanisms of action of intracerebral neural implants-studies on nigral and striatal grafts to the lesioned striatum. Trends Neurosci. 1987, 10:509-516.
20. Blanchard V., Anglade P., Dziewczapolski G., Savasta M., Agid Y., Raisman-Vozari R. Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra. Brain Res. 1996, 709:319-325.
21. Bódi N., Keri S., Nagy H., Moustafa A., Myers C.E., Daw N., Dibo G., Takats A., Bereczki D., Gluck M.A. Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients. Brain 2009, 132:2385-2395.
22. Bogdanova Y., Cronin-Golomb A. Neurocognitive correlates of apathy and anxiety in Parkinson's disease. Parkinsons Dis. 2012, article ID, 793076.
23. Bohnen N.I., Albin R.L. The cholinergic system and Parkinson disease. Behav. Brain Res. 2011, 221:564-573.
24. Branchi I., DAndrea I., Armida M., Cassano T., Pezzola A., Potenza R.L., Morgese M.G., Popoli P., Alleva E. Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J. Neurosci. Res. 2008, 86:2050-2061.
25. Branchi I., D'Andrea I., Armida M., Carnevale D., Ajmone-Cat M.A., Pezzola A., Potenza R.L., Morgese M.G., Cassano T., Minghetti L., Popoli P., Alleva E. Striatal 6-OHDA lesion in mice: investigating early neurochemical changes underlying Parkinson's disease. Behav. Brain Res. 2010, 208:137-143.
26. Brasted P., Humby T., Dunnett S.B., Robbins T.W. Unilateral lesions of the dorsal striatum in rats disrupt responding in egocentric space. J. Neurosci. 1997, 17:8919-8926.
27. Brecknell J.E., Haque N.S., Du J.S., Muir E.M., Fidler P.S., Hlavin M.L., Fawcett J.W., Dunnett S.B. Functional and anatomical reconstruction of the 6-hydroxydopamine lesioned nigrostriatal system of the adult rat. Neuroscience 1996, 71:913-925.
28. Brown V.J., Robbins T.W. Deficits in response space following unilateral striatal dopamine depletion in the rat. J. Neurosci. 1989, 9:983-989.
29. Calaminus C., Hauber W. Modulation of behavior by expected reward magnitude depends on dopamine in the dorsomedial striatum. Neurotox. Res. 2009, 15:97-110.
30. Carli M., Evenden J.L., Robbins T.W. Depletion of unilateral striatal dopamine impairs initiation of contralateral actions and not sensory attention. Nature 1985, 313:679-682.
31. Cenci M.A., Kalén P., Duan W.M., Björklund A. Transmitter release from transplants of fetal ventral mesencephalon and locus coeruleus in the rat frontal cortex and nucleus accumbens: effects of pharmacological and behavioural activating stimuli. Brain Res. 1994, 641:225-248.
32. Chaudhuri K.R., Schapira A.H. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009, 8:464-474.
33. Chaudhuri K.R., Healy D.G., Schapira A.H. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006, 5:235-245.
34. Chen L., Liu J., Ali U., Gui Z.H., Hou C., Fan L.L., Wang Y., Wang T. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist produces anxiolytic-like effects and reverses abnormal firing activity of projection neurons in the basolateral nucleus of the amygdala in rats with bilateral 6-OHDA lesions. Brain Res. Bull. 2011, 84:215-223.
35. Chen L., Liu J., Zhang Q.J., Feng J.J., Gui Z.H., Ali U., Wang Y., Fan L.L., Hou C., Wang T. Alterations of emotion, cognition and firing activity of the basolateral nucleus of the amygdala after partial bilateral lesions of the nigrostriatal pathway in rats. Brain Res. Bull. 2011, 85:329-338.
36. Cheshire P.A., Williams D.R. Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease. J. Clin. Neurosci. 2012, 19:343-348.
37. Chesselet M.F., Richter F. Modelling of Parkinson's disease in mice. Lancet Neurol. 2011, 10:1108-1118.
38. Colzato L.S., van den Wildenberg W.P., van Wouwe N.C., Pannebakker M.M., Hommel B. Dopamine and inhibitory action control: evidence from spontaneous eye blink rates. Exp. Brain Res. 2009, 196:467-474.
39. Cools R., D'Esposito M. Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol. Psychiatry 2011, 69:e113-e125.
40. Cordeiro K.K., Jiang W., Papazoglou A., Tenorio S.B., Döbrössy M.D., Nikkhah G. Graft-mediated functional recovery on a skilled forelimb use paradigm in a rodent model of Parkinson's disease is dependent on reward contingency. Behav. Brain Res. 2010, 212:187-195.
41. Cousins M.S., Salamone J.D. Nucleus accumbens dopamine depletions in rats affect relative response allocation in a novel cost/benefit procedure. Pharmacol. Biochem. Behav. 1994, 49:85-91.
42. Crowne D.P., Richardson C.M. A method to section the corpus callosum in the rat. Physiol. Behav. 1985, 34:847-850.
43. Croxson P.L., Walton M.E., O'Reilly J.X., Behrens T.E., Rushworth M.F. Effort-based cost-benefit valuation and the human brain. J. Neurosci. 2009, 29:4531-4541.
44. Dehay B., Bezard E. New animal models of Parkinson's disease. Mov. Disord. 2011, 26:1198-1205.
45. de Wit S., Barker R.A., Dickinson A.D., Cools R. Habitual versus goal-directed action control in Parkinson disease. J. Cogn. Neurosci. 2011, 23:1218-1229.
46. de Wit S., Standing H.R., Devito E.E., Robinson O.J., Ridderinkhof K.R., Robbins T.W., Sahakian B.J. Reliance on habits at the expense of goal-directed control following dopamine precursor depletion. Psychopharmacology 2012, 219:621-631.
47. Dickson D.W., Fujishiro H., Orr C., DelleDonne A., Josephs K.A., Frigerio R., Burnett M., Parisi J.E., Klos K.J., Ahlskog J.E. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat. Disord. 2009, 15(Suppl. 3):S1-S5.
48. Djamshidian A., Averbeck B.B., Lees A.J., O'Sullivan S.S. Clinical aspects of impulsive compulsive behaviours in Parkinson's disease. J. Neurol. Sci. 2011, 310:183-188.
49. Döbrössy M.D., Le Moal M., Monatron M.F., Abrous D.N. Influence of the environment on the efficacy of intrastriatal dopaminergic grafts. Exp. Neurol. 2000, 165:172-183.
50. Dowd E., Dunnett S.B. Deficits in a lateralised associative learning task in dopamine-depleted rats, with selective recovery by dopamine-rich transplants. Eur. J. Neurosci. 2004, 20:1953-1959.
51. Dowd E., Dunnett S.B. Comparison of 6-hydroxydopamine-induced medial forebrain bundle and nigrostriatal terminal lesions in rats using a lateralised nose-poking task with low stimulus-response compatibility. Behav. Brain Res. 2005, 165:181-186.
52. Dowd E., Dunnett S.B. Comparison of 6-hydroxydopamine-induced medial forebrain bundle and nigrostriatal terminal lesions using a lateralised nose-poking task in rats. Behav. Brain Res. 2005, 159:153-161.
53. Dowd E., Dunnett S.B. Movement without dopamine: striatal dopamine is required to maintain but not to perform learned actions. Biochem. Soc. Trans. 2007, 35:428-432.
54. Dowd E., Monville C., Torres E.M., Dunnett S.B. The corridor task: a simple test of lateralised response selection and neglect sensitive to unilateral dopamine deafferentation and graft-derived replacement in the striatum. Brain Res. Bull. 2005, 68:24-30.
55. Duda J.E. Olfactory system pathology as a model of Lewy neurodegenerative disease. J. Neurol. Sci. 2010, 289:49-54.
56. Dunnett S.B. Motor functions of the nigrostriatal dopamine system: studies of lesions and behaviour. Handbook of Chemical Neuroanatomy. Vol. 21. Dopamine 2005, 235-299. Elsevier, Amsterdam. S.B. Dunnett, M. Bentivoglio, A. Björklund, T. Hökfelt (Eds.).
57. Dunnett S.B., Björklund A. Transplantation of dopamine neurons: extent and mechanisms of functional recovery in rodent models of Parkinson's disease. Dopamine Handbook 2010, 454-477. Oxford University Press, New York. L.L. Iversen, S.D. Iversen, S.B. Dunnett, A. Björklund (Eds.).
58. Dunnett S.B., Björklund A., Stenevi U., Iversen S.D. Grafts of embryonic substantia nigra reinnervating the ventrolateral striatum ameliorate sensorimotor impairments and akinesia in rats with 6-OHDA lesions of the nigrostriatal pathway. Brain Res. 1981, 229:209-217.
59. Dunnett S.B., Björklund A., Stenevi U., Iversen S.D. Behavioral recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. 1. Unilateral lesions. Brain Res. 1981, 215:147-161.
60. Dunnett S.B., Björklund A., Schmidt R.H., Stenevi U., Iversen S.D. Intracerebral grafting of neuronal cell suspensions. IV. Behavioral recovery in rats with unilateral 6-OHDA lesions following implantation of nigral cell suspensions in different forebrain sites. Acta Physiol. Scand. Suppl. 1983, 522:29-37.
61. Dunnett S.B., Björklund A., Schmidt R.H., Stenevi U., Iversen S.D. Intracerebral grafting of neuronal cell suspensions. V. Behavioral recovery in rats with bilateral 6-OHDA lesions following implantation of nigral cell suspensions. Acta Physiol. Scand. Suppl. 1983, 522:39-47.
62. Dunnett S.B., Whishaw I.Q., Rogers D.C., Jones G.H. Dopamine-rich grafts ameliorate whole body motor asymmetry and sensory neglect but not independent limb use in rats with 6- hydroxydopamine lesions. Brain Res. 1987, 415:63-78.
63. Dunnett S.B., Hernandez T.D., Summerfield A., Jones G.H., Arbuthnott G.W. Graft-derived recovery from 6-OHDA lesions: specificity of ventral mesencephalic graft tissues. Exp. Brain Res. 1988, 71:411-424.
64. Dunnett S.B., Rogers D.C., Richards S.J. Nigrostriatal reconstruction after 6-OHDA lesions in rats: combination of dopamine-rich nigral grafts and nigrostriatal bridge grafts. Exp. Brain Res. 1989, 75:523-535.
65. Dunnett S.B., Meldrum A., Muir J.L. Frontal-striatal disconnection disrupts cognitive performance of the frontal-type in the rat. Neuroscience 2005, 135:1055-1065.
66. Fallon S.J., Williams-Gray C.H., Barker R.A., Owen A.M., Hampshire A. Prefrontal dopamine levels determine the balance between cognitive stability and flexibility. Cereb. Cortex 2012, Feb 20. [Epub ahead of print].
67. Faure A., Haberland U., Conde F., El Massioui N. Lesion to the nigrostriatal dopamine system disrupts stimulus-response habit formation. J. Neurosci. 2005, 25:2771-2780.
68. Faure A., Leblanc-Veyrac P., El Massioui N. Dopamine agonists increase perseverative instrumental responses but do not restore habit formation in a rat model of Parkinsonism. Neuroscience 2010, 168:477-486.
69. Ferrer I., Martinez A., Blanco R., Dalfo E., Carmona M. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J. Neural Transm. 2011, 118:821-839.
70. Ferro M.M., Bellissimo M.I., Anselmo-Franci J.A., Angellucci M.E.M., Canteras N.S., Da Cunha C. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J. Neurosci. Methods 2005, 148:78-87.
71. Fray P.J., Dunnett S.B., Iversen S.D., Björklund A., Stenevi U. Nigral transplants reinnervating the dopamine-depleted neostriatum can sustain intracranial self stimulation. Science 1983, 219:416-419.
72. Gage F.H., Dunnett S.B., Stenevi U., Björklund A. Aged rats: recovery of motor impairments by intrastriatal nigral grafts. Science 1983, 221:966-969.
73. Gallagher D.A., Lees A.J., Schrag A. What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them?. Mov. Disord. 2010, 25:2493-2500.
74. Haddon J.E., Killcross S. Rat prefrontal dopamine and cognitive control: impaired and enhanced conflict performance. Behav. Neurosci. 2011, 125:344-349.
75. Hanna K.K., Cronin-Golomb A. Impact of anxiety on quality of life in Parkinson's disease. Parkinsons Dis. 2012, Article ID, 640707.
76. Hefti F., Melamed E., Sahakian B.J., Wurtman R.J. Circling behavior in rats with partial, unilateral nigro-striatal lesions: effects of amphetamine, apomorphine, and DOPA. Pharmacol. Biochem. Behav. 1980, 12:185-188.
77. Herman J.P., Choulli K., Geffard M., Nadaud D., Taghzouti K., Le Moal M. Reinnervation of the nucleus accumbens and frontal cortex of the rat by dopaminergic grafts and effects on hoarding behavior. Brain Res. 1986, 372:210-216.
78. Herman J.P., Choulli K., Abrous D.N., Dulluc J., Le Moal M. Effects of intra-accumbens grafts on behavioral deficits induced by 6-OHDA lesions of the nucleus accumbens or A10 dopaminergic neurons: a comparison. Behav. Brain Res. 1988, 29:73-83.
79. Heuer A., Lelos M.J., Kelly C.M., Torres E.M., Dunnett S.B. Nigral grafts alleviate unilateral 6-OHDA-induced lateralised choice reaction time deficits in a rat model of PD. Exp. Neurol. 2012, (submitted).
80. Hwynn N., Haq I.U., Malaty I.A., Resnick A.S., Okun M.S., Carew D.S., Oyama G., Dai Y., Wu S.S., Rodriguez R.L., Jacobson C.E., Fernandez H.H. The frequency of nonmotor symptoms among advanced Parkinson patients may depend on instrument used for assessment. Parkinsons Dis. 2011, Article ID, 290195.
81. Ikemoto S. Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res. Rev. 2007, 56:27-78.
82. Jain S. Multi-organ autonomic dysfunction in Parkinson disease. Parkinsonism Relat. Disord. 2011, 17:77-83.
83. Jungnickel J., Kalve I., Reimers L., Nobre A., Wesemann M., Ratzka A., Halfer N., Lindemann C., Schwabe K., Tollner K., Gernert M., Grothe C. Topology of intrastriatal dopaminergic grafts determines functional and emotional outcome in neurotoxin-lesioned rats. Behav. Brain Res. 2011, 216:129-135.
84. Kapogiannis D., Mooshagian E., Campion P., Grafman J., Zimmermann T.J., Ladt K.C., Wassermann E.M. Reward processing abnormalities in Parkinson's disease. Mov. Disord. 2011, 26:1451-1457.
85. Kirik D., Winkler C., Björklund A. Growth and functional efficacy of intrastriatal nigral transplants depends on the extent of nigrostriatal degeneration. J. Neurosci. 2001, 21:2889-2896.
86. Knutson B., Taylor J., Kaufman M., Peterson R., Glover G. Distributed neural representation of expected value. J. Neurosci. 2005, 25:4806-4812.
87. Kurniawan I.T., Seymour B., Talmi D., Yoshida W., Chater N., Dolan R.J. Choosing to make an effort: the role of striatum in signaling physical effort of a chosen action. J. Neurophysiol. 2010, 104:313-321.
88. Lawrence A.D. Error correction and the basal ganglia: similar computations for action, cognition and emotion?. Trends Cogn. Sci. 2000, 4:365-367.
89. Lee J., Zhu W.M., Stanic D., Finkelstein D.I., Horne M.H., Henderson J., Lawrence A.J., OConnor L., Tomas D., Drago J., Horne M.K. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinesia. Brain 2008, 131:1574-1587.
90. Lees A.J., Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983, 106(Pt. 2):257-270.
91. Lelos M.J., Dunnett S.B. Aberrant dopamine transmission and cognitive dysfunction in animal models of Parkinson's disease. J. Parkinsons Dis. 2011, 1:151-165.
92. Lewis S.J., Slabosz A., Robbins T.W., Barker R.A., Owen A.M. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. Neuropsychologia 2005, 43:823-832.
93. Lex B., Hauber W. The role of dopamine in the prelimbic cortex and the dorsomedial striatum in instrumental conditioning. Cereb. Cortex 2010, 20:873-883.
94. Lindvall O. Clinical experiences with dopamine neuron replacement in Parkinson's disease: what is the future?. Dopamine Handbook 2010, 478-488. Oxford University Press, New York. L.L. Iversen, S.D. Iversen, S.B. Dunnett, A. Björklund (Eds.).
95. Lindvall O., Kokaia Z. Stem cells in human neurodegenerative disorders-time for clinical translation?. J. Clin. Invest. 2010, 120:29-40.
96. Lindvall O., Brundin P., Widner H., Rehncrona S., Gustavii B., Frackowiak R., Leenders K.L., Sawle G., Rothwell J.C., Marsden C.D., Björklund A. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990, 247:574-577.
97. Luciana M., Collins P.F., Depue R.A. Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. Cereb. Cortex 1998, 8:218-226.
98. Mackintosh N.J. The Psychology of Animal Learning 1974, Academic Press, London.
99. Madrazo I., Drucker-Colín R., Díaz V., Martínez-Mata J., Torres C., Becerril J.J. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. N. Engl. J. Med. 1987, 316:831-834.
100. Marsden C.D. The mysterious motor function of the basal ganglia. Neurology 1992, 32:514-539.
101. Marshall J.F., Levitan D., Stricker E.M. Activation-induced restoration of sensorimotor functions in rats with dopamine-depleting brain lesions. J. Comp. Physiol. Psychol. 1976, 90:536-546.
102. Ma Y., Tang C., Chaly T., Greene P., Breeze R., Fahn S., Freed C., Dhawan V., Eidelberg D. Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes. J. Nucl. Med. 2010, 7-15.
103. Montoya C.P., Astell S., Dunnett S.B. Effects of nigral and striatal grafts on skilled forelimb use in the rat. Prog. Brain Res. 1990, 82:459-466.
104. Murphy E., Lindgren H.S., Lelos M., Dunnett S.B., Lane E.L. Chronic L-DOPA administration has long term consequences on complex motor function. Neuropsychopharmacology 2012, (submitted).
105. Nadaud D., Herman J.P., Simon H., Le Moal M. Functional recovery following transplantation of ventral mesencephalic cells in rats subjected to 6-OHDA lesions of the mesolimbic dopaminergic neurons. Brain Res. 1984, 304:137-141.
106. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog. Neurobiol. 2002, 67:53-83.
107. Nikkhah G., Duan W.M., Knappe U., Jödicke A., Björklund A. Restoration of complex sensorimotor behavior and skilled forelimb use by a modified nigral cell suspension transplantation approach in the rat parkinson model. Neuroscience 1993, 56:33-43.
108. Nikkhah G., Cunningham M.G., Cenci M.A., McKay R.D., Björklund A. Dopaminergic microtransplants into the substantia nigra of neonatal rats with bilateral 6-OHDA lesions. I. Evidence for anatomical reconstruction of the nigrostriatal pathway. J. Neurosci. 1995, 15:3548-3561.
109. Nikkhah G., Cunningham M.G., McKay R., Björklund A. Dopaminergic microtransplants into the substantia nigra of neonatal rats with bilateral 6-OHDA lesions. II. Transplant-induced behavioral recovery. J. Neurosci. 1995, 15:3562-3570.
110. Nikkhah G., Eberhard J., Olsson M., Björklund A. Preservation of fetal ventral mesencephalic cells by cool storage: in-vitro viability and TH-positive neuron survival after microtransplantation to the striatum. Brain Res. 1995, 687:22-34.
111. Öberg R.G.E., Divac I. "Cognitive" functions of the neostriatum. The Neostriatum 1979, 291-313. Pergamon Press, Oxford. I. Divac, R.G.E. öberg (Eds.).
112. Obeso I., Wilkinson L., Casabona E., Bringas M.L., Alvarez M., Alvarez L., Pavon N., Rodriguez-Oroz M.C., Macias R., Obeso J.A., Jahanshahi M. Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson's disease. Exp. Brain Res. 2011, 212:371-384.
113. Olsson M., Nikkhah G., Bentlage C., Björklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci. 1995, 15:3863-3875.
114. Ostrosky-Solis F., Quintanar L., Madrazo I., Drucker-Colín R., Franco-Bourland R., Leonmeza V. Neuropsychological effects of brain autograft of adrenal medullary tissue for the treatment of Parkinson's disease. Neurology 1988, 38:1442-1450.
115. Owen A.M., James M., Leigh P.N., Summers B.A., Marsden C.D., Quinn N.P., Lange K.W., Robbins T.W. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 1992, 115:1727-1751.
116. Perlow M.J., Freed W.J., Hoffer B.J., Seiger Å., Olson L., Wyatt R.J. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 1979, 204:643-647.
117. Pessiglione M., Schmidt L., Draganski B., Kalisch R., Lau H., Dolan R.J., Frith C.D. How the brain translates money into force: a neuroimaging study of subliminal motivation. Science 2007, 316:904-906.
118. Politis M., Wu K., Loane C., Quinn N.P., Brooks D.J., Rehncrona S., Björklund A., Lindvall O., Piccini P. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci. Transl. Med. 2010, 2:38ra46.
119. Politis M., Oertel W.H., Wu K., Quinn N.P., Pogarell O., Brooks D.J., Björklund A., Lindvall O., Piccini P. Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin/dopamine transporter ratio. Mov. Disord. 2011, 26:1997-2003.
120. Quinn N.P. The clinical application of cell grafting techniques in patients with Parkinson's disease. Prog. Brain Res. 1990, 82:619-625.
121. Redgrave P., Rodriguez M., Smith Y., Rodriguez-Oroz M.C., Lehericy S., Bergman H., Agid Y., DeLong M.R., Obeso J.A. Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nat. Rev. Neurosci. 2010, 11:760-762.
122. Relja M., Klepac N. A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease. J. Neurol. Sci. 2006, 248:251-254.
123. Rozas G., Labandeira-García J.L. Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test. Brain Res. 1997, 749:188-199.
124. Sass K.J., Buchanan C.P., Westerveld M., Marek K.L., Farhi A., Robbins R.J., Naftolin F., Vollmer T.L., Leranth C., Roth R.H., Price L.H., Bunney B.S., Elsworth J.D., Hoffer P.B., Redmond D.E., Spencer D.D. General cognitive ability following unilateral and bilateral fetal ventral mesencephalic tissue transplantation for treatment of Parkinson's disease. Arch. Neurol. 1995, 52:680-686.
125. Sawamoto N., Piccini P., Hotton G., Pavese N., Thielemans K., Brooks D.J. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain 2008, 131:1294-1302.
126. Schultz W. Predictive reward signal of dopamine neurons. J. Neurophysiol. 1998, 80:1-27.
127. Schultz W. Reward signaling by dopamine neurons. Neuroscientist 2001, 7:293-302.
128. Schultz W. Getting formal with dopamine and reward. Neuron 2002, 36:241-263.
129. Seppi K., Weintraub D., Coelho M., Perez-Lloret S., Fox S.H., Katzenschlager R., Hametner E.M., Poewe W., Rascol O., Goetz C.G., Sampaio C. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov. Disord. 2011, 26(Suppl. 3):S42-S80.
130. Shore D.M., Rafal R., Parkinson J.A. Appetitive motivational deficits in individuals with Parkinson's disease. Mov. Disord. 2011, 26:1887-1892.
131. Stanic D., Finkelstein D.I., Bourke D.W., Drago J., Horne M.K. Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat. Eur. J. Neurosci. 2003, 18:1175-1188.
132. Steele-Russell I. The use of commissurotomy in studies of interhemispheric communication. Animal Models of Movement Disorders: Volume II. Neuromethods Vol. 62 2011, 211-238. Springer/Humana, New York. E.L. Lane, S.B. Dunnett (Eds.).
133. Suzuki K., Miyamoto M., Miyamoto T., Iwanami M., Hirata K. Sleep disturbances associated with Parkinson's disease. Parkinsons Dis. 2011, Article ID, 219056.
134. Tadaiesky M.T., Dombrowski P.A., Figueiredo C.P., Cargnin-Ferreira E., Da Cunha C., Takahashi R.N. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008, 156:830-840.
135. Thompson L.H., Grealish S., Kirik D., Björklund A. Reconstruction of the nigro-striatal dopamine pathway in the adult mouse brain. Eur. J. Neurosci. 2009, 30:625-638.
136. Tobler P.N., O'Doherty J.P., Dolan R.J., Schultz W. Reward value coding distinct from risk attitude-related uncertainty coding in human reward systems. J. Neurophysiol. 2007, 97:1621-1632.
137. Torres E.M., Dowd E., Dunnett S.B. Recovery of functional deficits following early donor age (E12) ventral mesencephalic grafts in a rat model of Parkinson's disease. Neuroscience 2008, 154:631-640.
138. Trott C.T., Fahn S., Greene P., Dillon S., Winfield H., Winfield L., Kao R., Eidelberg D., Freed C.R., Breeze R.E., Stern Y. Cognition following bilateral implants of embryonic dopamine neurons in PD: a double blind study. Neurology 2003, 60:1938-1943.
139. Turle-Lorenzo N., Maurin B., Puma C., Chezaubernard C., Morain P., Baunez C., Nieoullon A., Amalric M. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease. J. Pharmacol. Exp. Ther. 2006, 319:914-923.
140. Turner B.H. Sensorimotor syndrome produced by lesions of the amygdala and lateral hypothalamus. J. Comp. Physiol. Psychol. 1973, 82:37-47.
141. Tzschentke T.M., Schmidt W.J. Functional relationship among medial prefrontal cortex, nucleus accumbens, and ventral tegmental area in locomotion and reward. Crit. Rev. Neurobiol. 2000, 14:131-142.
142. Ulusoy A., Decressac M., Kirik D., Björklund A. Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson's disease. Prog. Brain Res. 2010, 184:89-111.
143. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res. 1970, 24:485-493.
144. Van Eimeren T., Ballanger B., Pellecchia G., Miyasaki J.M., Lang A.E., Strafella A.P. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?. Neuropsychopharmacology 2009, 34:2758-2766.
145. Whishaw I.Q., Dunnett S.B. Dopamine depletion, stimulation or blockade in the rat disrupts spatial navigation and locomotion dependent upon beacon or distal cues. Behav. Brain Res. 1985, 18:11-29.
146. Wilby M., Sinclair S.R., Muir E.M., Zietlow R., Adcock K.H., Horellou P., Dunnett S.B., Fawcett J.W. A GDNF-secreting clone of the Schwann cell line SCTM41 enhances survival and fibre outgrowth from embryonic nigral neurones grafted to the striatum and the lesioned substantia nigra. J. Neurosci. 1999, 19:2301-2312.
147. Williams G.V., Goldman-Rakic P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995, 376:572-575.
148. Wise R.A. Dopamine, learning and motivation. Nat. Rev. Neurosci. 2004, 5:483-494.
149. Zahrt J., Taylor J.R., Mathew R.G., Arnsten A.F. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J. Neurosci. 1997, 17:8528-8535.
150. Zhang W.Q., Tilson H.A., Nanry K.P., Hudson P.M., Hong J.S., Stachowiak M.K. Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage. Brain Res. 1988, 461:335-342.
151. Zhou F.C., Chiang Y.H., Wang Y. Constructing a new nigrostriatal pathway in the Parkinsonian model with bridged neural transplantation in substantia nigra. J. Neurosci. 1996, 16:6965-6974.
152. Zigmond M.J., Stricker E.M. Recovery of feeding and drinking by rats after intraventricular 6-hydroxydopamine or lateral hypothalamic lesions. Science 1973, 182:717-720.